DrugPatentWatch Database Preview
Desmopressin acetate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for desmopressin acetate and what is the scope of freedom to operate?
Desmopressin acetate
is the generic ingredient in eleven branded drugs marketed by Ferring Pharms Inc, Am Regent, Bedford, Hospira, Sagent Pharms Inc, Sun Pharm Inds Ltd, Teva Pharms Usa, Ferring, Sun Pharm Inds, Bausch And Lomb, Apotex Inc, Sun Pharm, Zydus Pharms, Alyvant, Abhai Llc, Actavis Labs Fl Inc, Glenmark Pharms Ltd, Heritage Pharma, Impax Labs Inc, Mylan, and Novast Labs, and is included in thirty NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Desmopressin acetate has one hundred and eighty-four patent family members in thirty-five countries.
There are twenty drug master file entries for desmopressin acetate. Twenty-one suppliers are listed for this compound.
Summary for desmopressin acetate
| International Patents: | 184 |
| US Patents: | 13 |
| Tradenames: | 11 |
| Applicants: | 21 |
| NDAs: | 30 |
| Drug Master File Entries: | 20 |
| Suppliers / Packagers: | 21 |
| Bulk Api Vendors: | 107 |
| Clinical Trials: | 4 |
| Patent Applications: | 1,002 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for desmopressin acetate |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for desmopressin acetate |
| DailyMed Link: | desmopressin acetate at DailyMed |
Recent Clinical Trials for desmopressin acetate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| University Hospitals Cleveland Medical Center | Phase 2 |
| Teva Pharmaceuticals USA | Phase 1 |
Recent Litigation for desmopressin acetate
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ferring B v. v. Allergan Inc. | 2012-04-05 |
| Ferring BV v. Teva Pharmaceuticals | 2004-07-20 |
Pharmacology for desmopressin acetate
| Drug Class | Factor VIII Activator Vasopressin Analog |
| Physiological Effect | Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration |
Synonyms for desmopressin acetate
| (Deamino-Cys1,D-Arg8)-Vasopressin |
| 1-(3-Mercaptopropanoic Acid)-8-d-arginine Vasopressin Monoacetate |
| 1-(3-mercaptopropanoic acid)-8-D-arginine vasopression monoacetate trihydrate |
| 1-(3-Mercaptopropanoic acid)-8-D-argininevasopressin monoacetate (salt), trihydrate |
| 1-(3-Mercaptopropionic acid)-8-D-arginine vasopression monoacetate |
| 1-(3-mercaptopropionic acid)-8-D-arginine vasopression monoacetate trihydrate |
| 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin |
| 1-(3-Mercaptopropionic acid)-8-D-arginine-vasopressin diacetate |
| 1-(3-Mercaptopropionic acid)-8-D-arginine-vasopressin monoacetate (salt) trihydrate |
| 1-(7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-(1-((2-amino-2-o |
| 1-{[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-D-arginylglycinamide |
| 1-{[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyl-n5-(diaminomethylidene)ornithylglycinamide acetate(1:1) |
| 1-{[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyl-n5-(diaminomethylidene)ornithylglycinamide acetate(1:2) |
| 1-Deamino-8-D-arginine vasopressin |
| 1-deamino-8-D-arginine vasopressin acetate trihydrate |
| 1-Deamino-8-D-arginine-vasopressin diacetate |
| 1-Desamino-8-D-arginine vasopressin |
| 1-desamino-8-D-arginine vasopressin acetate trihydrate |
| 16679-58-6 |
| 16679-58-6 (Parent) |
| 16789-98-3 |
| 1K12647SFC |
| 242K8LE2BC |
| 3576AH |
| 3577AH |
| 357D862 |
| 62288-83-9 |
| 62288-83-9 (monoacetate) |
| 62357-86-2 |
| 62357-86-2 (monoacetate trihydrate) |
| 679D586 |
| 789D983 |
| 8-d-Arginine-1-(3-mercapto-propanoic Acid)vasopresin Monoacetate |
| A810919 |
| A833738 |
| ABP000576 |
| AC1L21V2 |
| AC1L21V5 |
| AC1L506T |
| AC1NSJXN |
| AC1Q5SZE |
| AC1Q5T0K |
| Adiuretin SD |
| AKOS015994650 |
| AKOS025311518 |
| AKOS030485983 |
| AKOS030573306 |
| AN-7545 |
| BCP13206 |
| BCP15458 |
| BDBM50205308 |
| C46H64N14O12S2 |
| C46H64N14O12S2.C2H4O2 |
| C46H64N14O12S2.C2H4O2.3H2O |
| CAS-62288-83-9 |
| CD-644 |
| CHEBI:4450 |
| CHEBI:59728 |
| CHEMBL1200556 |
| CHEMBL1429 |
| CHEMBL2138698 |
| CHEMBL2358584 |
| CONCENTRAID |
| CS-0952 |
| CTK8F9082 |
| D02235 |
| DDAVP |
| DDAVP (NEEDS NO REFRIGERATION) |
| DDAVP (TN) |
| DDAVP ACETATE |
| DDAVP Nasal Spray |
| DDAVP Rhinal Tube |
| Deamino Arginine Vasopressin |
| Deamino-8-D-arginine, l-, vasopressin |
| Demopressin acetate |
| Desamino-8-D-arginine vasopressin, l- |
| Desmopresina |
| Desmopresina [INN-Spanish] |
| DESMOPRESSIN |
| Desmopressin (Acetate) |
| Desmopressin [INN:BAN] |
| Desmopressin acetate (needs NO refrigeration) |
| Desmopressin acetate (USAN) |
| Desmopressin acetate [USAN:JAN] |
| Desmopressin acetate [USAN:USP:JAN] |
| Desmopressin acetate anhydrous |
| Desmopressin acetate hydrate |
| Desmopressin acetate hydrate (JAN) |
| DESMOPRESSIN ACETATE PRESERVATIVE FREE |
| Desmopressin acetate trihydrate |
| Desmopressin Acetate(1:2) |
| Desmopressin Acetate(STIMATE, DDAVP)/ |
| Desmopressin diacetate |
| Desmopressin diacetate anhydrous |
| Desmopressine |
| Desmopressine [INN-French] |
| Desmopressinum |
| Desmopressinum [INN-Latin] |
| Desmospray |
| DSSTox_CID_26864 |
| DSSTox_GSID_46864 |
| DSSTox_RID_81971 |
| DTXSID4046864 |
| EINECS 240-726-7 |
| ENR1LLB0FP |
| FT-0603106 |
| FT-0624526 |
| FT-0653786 |
| FT-0688024 |
| H661 |
| HS-2010 |
| HY-17370 |
| KS-00002WUQ |
| KW-8008 |
| LS-161413 |
| Minirin |
| Minirine |
| Minirinmelt (TN) |
| MLSVJHOYXJGGTR-IFHOVBQLSA-N |
| MolPort-006-069-425 |
| NCGC00181133-01 |
| NCGC00181133-02 |
| NCGC00263573-01 |
| NFLWUMRGJYTJIN-PNIOQBSNSA-N |
| Octim |
| Octostim |
| Presinex |
| SC-18848 |
| SCHEMBL1172203 |
| SCHEMBL14027607 |
| SCHEMBL204511 |
| Stimate |
| Stimate (TN) |
| Stimate injection |
| Stimate Nasal Spray |
| Tox21_112740 |
| Tox21_112740_1 |
| UNII-1K12647SFC |
| UNII-242K8LE2BC |
| UNII-ENR1LLB0FP |
| UNII-XB13HYU18U |
| VA10693 |
| Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- |
| Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-, diacetate (salt) |
| Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-, monoacetate (salt) |
| Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-, monoacetate (salt), trihydrate |
| W-5074 |
| XB13HYU18U |
| xoethyl)amino)-5-((diaminomethylene)amino)-1-oxopentan-2-yl)pyrrolidine-2-carboxamide diacetate |
Paragraph IV (Patent) Challenges for DESMOPRESSIN ACETATE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| DDAVP | INJECTABLE;INJECTION | desmopressin acetate | 018938 | |
| DDAVP | SOLUTION;NASAL | desmopressin acetate | 017922 | |
| DDAVP | TABLET;ORAL | desmopressin acetate | 019955 | |
| DDAVP | SPRAY, METERED;NASAL | desmopressin acetate | 017922 | |
| DDAVP (NEEDS NO REFRIGERATION) | SPRAY, METERED;NASAL | desmopressin acetate | 017922 |
US Patents and Regulatory Information for desmopressin acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | DDAVP | desmopressin acetate | SOLUTION;NASAL | 017922-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Apotex Inc | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | desmopressin acetate | SPRAY, METERED;NASAL | 076703-001 | Jan 27, 2005 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for desmopressin acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | DDAVP | desmopressin acetate | TABLET;ORAL | 019955-001 | Sep 6, 1995 | Start Trial | Start Trial |
| Ferring Pharms Inc | DDAVP (NEEDS NO REFRIGERATION) | desmopressin acetate | SPRAY, METERED;NASAL | 017922-003 | Aug 7, 1996 | Start Trial | Start Trial |
| Ferring Pharms Inc | DDAVP | desmopressin acetate | SOLUTION;NASAL | 017922-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for desmopressin acetate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 3225249 | Start Trial |
| Poland | 208482 | Start Trial |
| South Korea | 20170081711 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for desmopressin acetate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2712622 | LUC00015 | Luxembourg | Start Trial | PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101 |
| 3225249 | 300983 | Netherlands | Start Trial | PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513 |
| 3225249 | CA 2019 00023 | Denmark | Start Trial | PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.